Blueprint Medicines Receivables

Blueprint Medicines posts a receivables of $80M as of March 2025. That compares with $60M in the prior-year period — up 32.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Blueprint Medicines's receivables was $60M. The latest reading is $80M — a 32.9% year-over-year increase (period ending March 2025). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Blueprint Medicines's financial statement story. At $80M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BPMC's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Blueprint Medicines's other metric pages and overview cover the third.

Judging Blueprint Medicines against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $80M here, then scan peer and history charts to see if the gap is persistent.